ストックスクリーナーアプリを入手
7.28
1.52%
0.16
前日終値:
$7.12
開ける：
$7.25
24時間の取引高:
754
Relative Volume:
0.02
時価総額：
$29.68M
収益：
$6.44M
当期純損益:
$-58.21M
株価収益率:
0.2328
EPS:
31.2684
ネットキャッシュフロー:
$-4.86M
1週間 パフォーマンス:
+0.53%
1か月 パフォーマンス:
+3.26%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$7.22
$7.335
1週間の範囲:
$7.02
$7.455
52週間の値動き範囲:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Compare KYNB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
7.335 | 28.81M | 6.44M | -58.21M | -4.86M | 31.27 |
VRTX
Vertex Pharmaceuticals Inc
|
439.92 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.03 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
835.59 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.33 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
321.26 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-26 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-06-26 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | ダウングレード | Stifel | Buy → Hold |
| 2023-06-26 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | アップグレード | Stifel | Hold → Buy |
| 2023-01-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-09-22 | ダウングレード | Goldman | Neutral → Sell |
| 2021-08-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-07-16 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-03-31 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-03-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-01 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-26 | 開始されました | Raymond James | Underperform |
| 2020-07-10 | 再開されました | Stifel | Buy |
すべてを表示
Kyntra Bio Inc (KYNB) 最新ニュース
Kyntra Bio (KYNB) upgraded to buy: Here's what you should know - MSN
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
What date does Kyntra Bio Inc's (KYNB) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Kyntra Bio Faces Nasdaq Compliance Challenge After Revenue Shift - TipRanks
Kyntra Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
KYNB Stock Price, Quote & Chart | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Kyntra Bio CEO to webcast April 13 presentation at Needham event - Stock Titan
KYNB PE Ratio & Valuation, Is KYNB Overvalued - Intellectia AI
FGEN SEC FilingsFibrogen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kyntra Bio (MEX:KYNB) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
Kyntra Bio, Inc.Common Stock (NQ: KYNB - FinancialContent
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
If You Invested $1,000 in Fibrogen Inc (FGEN) - Stock Titan
Advancing Pipeline and 2026 Clinical Catalysts Underpin Buy Rating on Kyntra Bio - tipranks.com
Kyntra Bio, Inc. 2023 Annual Report: Business Overview, Risk Factors, and Financial Highlights - Minichart
Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ... By GuruFocus - Investing.com Canada
Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigati - GuruFocus
Maintaining a Hold on Kyntra Bio Amid Pipeline Refocus and Pending Clinical Inflection Points - TipRanks
Kyntra Bio 2025 Review: Clinical Progress on Cancer Drugs and Future OutlookNews and Statistics - IndexBox
KYNB: Cash runway extended to 2028 as FG-3246 and roxadustat advance in key late-stage trials - TradingView
Kyntra Bio (KYNB) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kyntra Bio, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-03-16 - Seeking Alpha
Kyntra Bio: Fourth Quarter Financial Overview - Bitget
Kyntra Bio: Q4 Earnings Snapshot - marketscreener.com
Kyntra Bio reports $6.44M revenue, $45.37 EPS on divestiture gain - TradingView
Kyntra Bio (NASDAQ: KYNB) pivots to oncology and advances FG-3246, roxadustat - Stock Titan
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
KYNB: Revenue fell but net loss improved; clinical and regulatory milestones achieved - TradingView
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
New prostate cancer drug trial advances as Kyntra Bio cuts 2025 loss - Stock Titan
FibroGen (KYNB) Set to Announce Q4 Earnings with Significant Dec - gurufocus.com
KYNB: Lead oncology and anemia programs advance with strong data, regulatory clarity, and commercial promise - TradingView
Kyntra Bio : Corporate Presentation – March 2026 - marketscreener.com
Kyntra Bio (KYNB) CEO reports 277-share tax withholding event - Stock Titan
Tax withholding slightly trims Kyntra Bio (KYNB) CFO share holdings - Stock Titan
Kyntra Bio (KYNB) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - Bitget
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kyntra Bio (KYNB), Crispr Therapeutics AG (CRSP) and GoodRx Holdings (GDRX) - The Globe and Mail
KYNB Price History for Kyntra Bio Stock - Barchart.com
KYNB | Kyntra Bio, Inc. Common Institutional Ownership - Quiver Quantitative
Kyntra Bio reports prostate cancer trial results at ASCO GU - Investing.com South Africa
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246 - TipRanks
Kyntra Bio reports prostate cancer trial results at ASCO GU By Investing.com - Investing.com Australia
KYNB to Present FG-3246 Trial Data at ASCO GU 2026 - GuruFocus
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Kyntra Bio Inc (KYNB) 財務データ
収益
当期純利益
現金流量
EPS
Kyntra Bio Inc (KYNB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
1.33%
1.07%
大文字化:
|
ボリューム (24 時間):